Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study

Yuan Peng, Miao Liu, Xianan Li, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Hongjun Liu, Lin Cheng, Jiajia Guo, Fei Xie, Houpu Yang, Siyuan Wang, Chaobin Wang, Yalin Chen, Shu Wang, Yuan Peng, Miao Liu, Xianan Li, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Hongjun Liu, Lin Cheng, Jiajia Guo, Fei Xie, Houpu Yang, Siyuan Wang, Chaobin Wang, Yalin Chen, Shu Wang

Abstract

Background: Although the ACOSOG Z0011 study showed that axillary lymph node dissection (ALND) could be avoided in a specific population of sentinel lymph node-positive patients, it is not widely accepted by Chinese surgeons. We conducted a prospective single-arm study to confirm whether or not the results of Z0011 are applicable to Chinese patients.

Methods: Patients conforming to the Z0011 criteria were prospectively enrolled at the Peking University People's Hospital Breast Center from November 2014 to June 2019. The clinicopathological features of the study group were compared with those of the Z0011 study group. Lymphedema after surgery, the incidence of local-regional recurrence, and survival were analyzed.

Results: One hundred forty-two patients who met the Z0011 eligibility criteria were enrolled in this study; 115 underwent sentinel lymph node biopsy (SLNB) alone. Compared with the Z0011 trial, younger patients were included (median age, 52 [26-82] years vs 54 [25-90] years; P = 0.03). For clinical T stage, tumor histology, hormone status, lymphovascular invasion, and the number of positive sentinel lymph nodes (SLNs), no statistically significant differences were observed. More patients received adjuvant chemotherapy and endocrine therapy in this study (90.85% vs 58.0% and 80.99% vs 46.6% respectively, P <0.001). A similar percentage of patients received radiotherapy, but more nodal radiotherapy procedures were carried out in our study (54.5% vs 16.9%). After a median follow-up of 29 months, only 1 patient (0.9%) had ipsilateral breast tumor recurrence, and no regional recurrence occurred.

Conclusion: Our study showed that it is achievable to avoid ALND in patients eligible for Z0011 in China.

Trial registration: ClinicalTrials.gov. Registration number NCT03606616 . Retrospectively registered on 31 July 2018.

Keywords: ACOSOG Z0011; Breast cancer; Chinese; Sentinel lymph node.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the study procedures
Fig. 2
Fig. 2
Radiotherapy field in the prospective studies

References

    1. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575. doi: 10.1001/jama.2011.90.
    1. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–926. doi: 10.1001/jama.2017.11470.
    1. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast, version 1.2012. . Accessed 30 Jun 2017. 3.
    1. Dengel LT, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast conserving therapy. Ann Surg Oncol. 2014;21:22–27. doi: 10.1245/s10434-013-3200-6.
    1. Delpech Y, et al. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study. Ann Surg Oncol. 2013;20:2556–2561. doi: 10.1245/s10434-013-2917-6.
    1. Aigner J, et al. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations. Ann Surg. 2013;20:1538–1544. doi: 10.1245/s10434-012-2798-0.
    1. Ngui NK, Elder EE, Jayasinghe UW, French J. Relevance of the American College of Surgeons Oncology Group Z0011 trial to breast cancer in the Australian setting. ANZ J Surg. 2013;83:924–928. doi: 10.1111/ans.12388.
    1. Kittaka N, Tokui R, Hashimoto Y, et al. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. Int J Clin Oncol. 2018;23:860–866. doi: 10.1007/s10147-018-1297-0.
    1. Jung J, Han W, Lee ES, et al. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Breast Cancer Res Treat. 2019;175:203–215. doi: 10.1007/s10549-019-05157-4.
    1. Morrow M, Van Zee KJ, Patil S, et al. Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers: a prospective validation study of 793 patients. Ann Surg. 2017;266:457–462. doi: 10.1097/SLA.0000000000002354.
    1. Jung J, Kim BH, Kim J, et al. Validating the ACOSOG Z0011 trial result: a population-based study using the SEER database. Cancers (Basel) 2020;12:950. doi: 10.3390/cancers12040950.
    1. Lee J, Choi JE, Kim SJ, et al. Comparative study between sentinel lymph node biopsy and axillary dissection in patients with one or two lymph node metastases. J Breast Cancer. 2018;21:306–314. doi: 10.4048/jbc.2018.21.e44.
    1. Morrow M, Jagsi R, McLeod MC, et al. Surgeon attitudes toward the omission of axillary dissection in early breast cancer. JAMA Oncol. 2018;4:1511–1516. doi: 10.1001/jamaoncol.2018.1908.
    1. Zhang X, Wang Y. A survey of current surgical treatment of early stage breast cancer in China. Oncoscience. 2018;5:239–247. doi: 10.18632/oncoscience.445.
    1. Liu M, Wang S, Cui S, et al. The feasibility of the ACOSOG Z0011 criteria to Chinese breast cancer patients: a multicenter study. Sci Rep. 2015;5:15241. doi: 10.1038/srep15241.
    1. Mei RF, Axelrod D, Cleland CM, et al. Symptom report in detecting breast cancer-related lymphedema. Breast Cancer. 2015;7:345–352.
    1. Garcia-Etienne CA, Mansel RE, Tomatis M, et al. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: impact of evidence on practice. Breast. 2019;45:89–96. doi: 10.1016/j.breast.2019.03.002.
    1. Ngui NK, Hitos K, Michael T, Hughes D, et al. Effect of the American College of Surgeons Oncology Group Z0011 trial on axillary management in breast cancer patients in the Australian setting. Breast J. 2019;25:853–858. doi: 10.1111/tbj.13343.
    1. Breast Cancer Committee of China Anti-Cancer Association Guidelines in breast cancer diagnosis and treatment of China Anti-Cancer Association (version 2019) Zhongguo Ai Zheng Za Zhi. 2019;29:609–680.
    1. Verheuvel NC, Voogd AC, Tjan-Heijnen VC, et al. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients. Eur J Surg Oncol. 2016;42:1162–1168. doi: 10.1016/j.ejso.2016.05.007.
    1. Yi M, Kuerer HM, Mittendorf EA, et al. Impact of the American College of Surgeons Oncology Group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013;216:105–113. doi: 10.1016/j.jamcollsurg.2012.09.005.
    1. Yuan L, Qi X, Zhang Y, et al. Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study. Cancer Biol Med. 2018;15:452–460. doi: 10.20892/j.issn.2095-3941.2018.0270.
    1. Valente SA, Al-Hilli Z, Radford DM, et al. Near infrared fluorescent lymph node mapping with indocyanine green in breast cancer patients: a prospective trial. J Am Coll Surg. 2019;228:672–678. doi: 10.1016/j.jamcollsurg.2018.12.001.
    1. Boland MR, Ni Cearbhail R, Fitzpatrick K, et al. A positive node on ultrasound-guided fine needle aspiration predicts higher nodal burden than a positive sentinel lymph node biopsy in breast carcinoma. World J Surg. 2016;40:2157–2162. doi: 10.1007/s00268-016-3557-3.
    1. Liang Y, Chen X, Tong Y, et al. Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. World J Surg Oncol. 2019;17:37. doi: 10.1186/s12957-019-1582-z.
    1. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24 Suppl 6:vi7–v23. doi: 10.1093/annonc/mdt284.
    1. Harnett A, Smallwood J, Titshall V, et al. Diagnosis and treatment of early breast cancer, including locally advanced disease summary of NICE guidance. BMJ. 2009;338:b438. doi: 10.1136/bmj.b438.
    1. Liu M, Yang Y, Xie F, et al. Could axillary clearance be avoided in clinically node-negative breast cancer patients with positive nodes diagnosed by ultrasound guided biopsy in the post-ACOSOG Z0011 ear? PLoS One. 2019;14:e0210437. doi: 10.1371/journal.pone.0210437.
    1. Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol. 2014;32:3600–3606. doi: 10.1200/JCO.2014.56.5838.
    1. Katz MS, McCall L, Ballman K, et al. Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations. Breast Cancer Res Treat. 2020;180:429–436. doi: 10.1007/s10549-020-05555-z.
    1. Raber BM, Lin H, Shen Y, et al. Trends in regional nodal management of breast cancer patients with low nodal burden. Ann Surg Oncol. 2019;26:4346–4354. doi: 10.1245/s10434-019-07901-y.
    1. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–3663. doi: 10.1200/JCO.2006.07.4062.
    1. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. doi: 10.1016/S1470-2045(13)70035-4.
    1. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–1310. doi: 10.1016/S1470-2045(14)70460-7.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться